The US National Institutes of Health (NIH) has renewed the Excellence in Neuroscience Clinical Trials (NeuroNEXT) research programme, which supports the streamline of Phase II clinical trials for brain disorders, to extend the programme for five additional years.

The renewal will see the joining of various new centres in the NeuroNEXT programme.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

NIH unit National Institute of Neurological Disorders and Stroke (NINDS) supports the programme, which was launched in 2011 to further efficient the neuroscience clinical trials and to help increase the number of treatments that get into clinical practice.

NINDS programme director Robin Conwit said: “One of the advantages of NeuroNEXT, and something that makes it unique, is the network’s ability to quickly mobilise a group of specialists from a certain disease area to initiate a clinical study when opportunities emerge for trials.

“The structure of NeuroNEXT, with its broad focus across neuroscience clinical studies, has the potential to reach many individuals who are affected by brain disorders.”

“The structure of NeuroNEXT, with its broad focus across neuroscience clinical studies, has the potential to reach many individuals who are affected by brain disorders.”

NeuroNEXT is expected to promote partnerships between academic centres, disease foundations, and industry.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Inexperienced researcher can apply to the NeuroNEXT programme and receive resources available at the participating centres of the programme if he/she wishes to conduct a Phase II clinical trial.

NINDS programme director Codrin Lungu said: “To date, nine clinical trials currently in various stages have been implemented in the NeuroNEXT network, showing that this innovative approach to research can help expedite clinical research and help get treatments to patients faster.

“We are thrilled to continue working with the sites that have been participating in the network, and we look forward to collaborating with the eight sites that will be joining the programme.”

NINDS primarily provides funding for research on the brain and nervous system.